All articles by Robert Barrie
Robert Barrie is a trainee reporter for Medical Device Network, covering developments in the healthcare sector. Coming from a scientific and medical background, Robert has reported across various topics with expertise in neuroscience, genetics, and epidemiology. Previously, he worked on a freelance basis with New Scientist.
Robert Barrie
FDA greenlights Neuralink for human trials
Elon Musk’s brain-implant company receives the go-ahead to move testing from animals to humans.
Clarity completes first stage of prostate cancer trial
Clarity has completed cohort 1 of its Phase I/II theranostic trial, SECuRE, and will now advance to cohort 2.
Michael J. Fox Foundation teams up with H1 to drive PD research engagement
H1 will provide a trial data platform to help the foundation reach underrepresented populations, connect with scientists, and aid education.
Corvia Medical’s atrial shunt therapy shows promise in randomised clinical trial
Two-year results from a Phase III trial showed heart failure patients demonstrated a reduction in heart failure events.
Abbott tout results from AVEIR DR pacemaker trial
The leadless dual-chamber pacemaker met primary endpoints for safety and performance.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Elixir’s coronary implant device meets primary endpoint at 12-months
The drug-eluting bioadaptor scaffold achieved 1.8% target lesion failure rate compared to 2.8% by a comparative stent.
Everest completes patient enrollment of etrasimod Phase III trial in Asia
The trial in Asia is evaluating the S1P receptor modulator in moderate-severe active ulcerative colitis treatment.
Patient enrollment completed for Phase II trial of AlphaMedix in neuroendocrine cancer
The Phase II trial is evaluating safety and effectiveness of the targeted alpha emitter therapy.
First patient dosed in TILT-123 Phase I trial
TILT Biotherapeutics’ candidate is an oncolytic adenovirus being assessed in a solid tumour trial.
First randomised Phase II trial using FLASH radiotherapy for NMSC treatment
The trial will compare FLASH radiotherapy to conventional radiotherapy in patients with skin cancer.